GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
G

Genertec Universal Medical Group Co 2666.HK · HKD

Health Care · HKEX · 🇭🇰 Hong Kong

Compare

4.70

-0.21%

Close of 9 Nov 2026, in HKD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in CNY, from our data supplier.

FY2025

Revenue

CN¥16.93bn

FY2016FY2025

Net income

CN¥2.57bn

FY2016FY2025

Free cash flow

CN¥3.59bn

FY2016FY2025

Shareholders' equity

CN¥22.46bn

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
RevenueCN¥16.93bnCN¥15.91bnCN¥15.90bnCN¥13.47bnCN¥11.14bnCN¥9.60bnCN¥7.86bnCN¥5.00bnCN¥3.99bnCN¥3.15bn
Gross profitCN¥5.89bnCN¥5.35bnCN¥5.32bnCN¥13.66bnCN¥11.14bnCN¥9.60bnCN¥3.62bnCN¥3.02bnCN¥2.54bnCN¥2.03bn
Research and developmentCN¥90.4mCN¥77.8mCN¥41.8mCN¥56.0mCN¥30.1mCN¥19.4mCN¥16.1m———
Operating incomeCN¥3.55bnCN¥3.59bnCN¥3.76bnCN¥12.03bnCN¥9.71bnCN¥8.42bnCN¥2.64bnCN¥2.28bnCN¥1.93bnCN¥1.38bn
Net incomeCN¥2.57bnCN¥2.45bnCN¥2.46bnCN¥2.28bnCN¥2.27bnCN¥2.03bnCN¥1.85bnCN¥1.57bnCN¥1.34bnCN¥1.02bn
Diluted earnings per share1.271.221.181.101.101.191.080.920.780.59

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assetsCN¥98.24bnCN¥100.19bnCN¥93.57bnCN¥89.52bnCN¥81.41bnCN¥71.64bnCN¥67.38bnCN¥55.04bnCN¥43.94bnCN¥33.73bn
Cash and short-term investmentsCN¥3.11bnCN¥2.77bnCN¥4.19bnCN¥3.15bnCN¥2.73bnCN¥2.37bnCN¥3.94bnCN¥2.53bnCN¥2.04bnCN¥1.48bn
Total liabilitiesCN¥70.88bnCN¥73.56bnCN¥69.85bnCN¥66.58bnCN¥60.88bnCN¥54.21bnCN¥51.72bnCN¥43.09bnCN¥35.25bnCN¥26.08bn
DebtCN¥56.40bnCN¥55.57bnCN¥51.14bnCN¥50.26bnCN¥44.17bnCN¥42.25bnCN¥40.00bnCN¥35.08bnCN¥28.76bnCN¥21.25bn
Shareholders' equityCN¥22.46bnCN¥21.96bnCN¥20.21bnCN¥18.20bnCN¥17.20bnCN¥14.47bnCN¥12.98bnCN¥11.70bnCN¥8.70bnCN¥7.66bn
Shares outstanding2,025m2,010m2,083m2,080m2,070m1,716m1,716m1,716m1,716m1,716m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operationsCN¥4.71bnCN¥1.33bnCN¥5.82bnCN¥2.40bn−CN¥1.63bn−CN¥1.13bn−CN¥2.12bn−CN¥6.67bn−CN¥5.91bn−CN¥2.77bn
Capital spending−CN¥1.12bn−CN¥1.46bn−CN¥1.04bn−CN¥708.2m−CN¥448.5m−CN¥467.5m−CN¥242.5m−CN¥20.5m−CN¥22.0m−CN¥23.5m
Free cash flowCN¥3.59bn−CN¥136.0mCN¥4.77bnCN¥1.69bn−CN¥2.08bn−CN¥1.60bn−CN¥2.37bn−CN¥6.69bn−CN¥5.93bn−CN¥2.80bn
Dividends paid−CN¥716.8m−CN¥704.0m−CN¥689.5m−CN¥676.0m−CN¥562.5m−CN¥528.9m−CN¥474.2m−CN¥392.2m−CN¥296.3m−CN¥219.5m

Latest quarters

By quarter end

Jun 2026Dec 2025Jun 2025Dec 2024Jun 2024Dec 2023Jun 2023Dec 2022
RevenueCN¥8.16bnCN¥8.20bnCN¥8.74bnCN¥8.05bnCN¥7.47bnCN¥8.03bnCN¥7.59bnCN¥7.19bn
Gross profitCN¥2.38bnCN¥8.20bnCN¥8.74bnCN¥8.05bnCN¥7.47bnCN¥8.09bnCN¥7.59bnCN¥6.99bn
Operating incomeCN¥1.73bnCN¥2.27bnCN¥7.65bnCN¥6.93bnCN¥6.52bnCN¥6.88bnCN¥1.69bnCN¥1.44bn
Net incomeCN¥1.47bnCN¥1.11bnCN¥1.47bnCN¥1.08bnCN¥1.37bnCN¥1.13bnCN¥1.27bnCN¥930.6m
Diluted earnings per share0.730.550.720.540.680.540.610.45
Cash from operations−CN¥481.0mCN¥3.00bnCN¥2.88bnCN¥3.62bn−CN¥2.30bnCN¥9.71bn−CN¥3.89bnCN¥3.90bn
Capital spending−CN¥453.0m−CN¥739.0m−CN¥406.0m−CN¥754.0m−CN¥707.0m−CN¥647.0m−CN¥397.0m−CN¥545.0m
Free cash flow−CN¥934.0mCN¥2.26bnCN¥2.48bnCN¥2.87bn−CN¥3.00bnCN¥9.06bn−CN¥4.29bnCN¥3.36bn
Total assetsCN¥101.21bnCN¥98.24bnCN¥99.83bnCN¥100.19bnCN¥97.79bnCN¥93.57bnCN¥98.12bnCN¥89.52bn
Cash and short-term investmentsCN¥3.34bnCN¥3.11bnCN¥2.61bnCN¥2.77bnCN¥3.30bnCN¥4.19bnCN¥2.92bnCN¥3.12bn
DebtCN¥29.20bnCN¥56.40bnCN¥60.44bnCN¥61.66bnCN¥58.68bnCN¥56.70bnCN¥62.38bnCN¥55.16bn
Shareholders' equityCN¥23.25bnCN¥22.46bnCN¥21.84bnCN¥21.96bnCN¥22.27bnCN¥20.21bnCN¥19.56bnCN¥18.20bn

Financial ratios

Data as of 4 Oct 2026

FY2025FY2024FY2023FY2022FY2021FY2020
Gross margin34.8%33.6%33.5%101.4%100.0%100.0%
Operating margin21.0%22.6%23.7%89.3%87.2%87.7%
Net margin15.2%15.4%15.5%16.9%20.4%21.2%
Return on equity11.5%11.2%12.2%12.5%13.2%14.1%
Return on assets2.6%2.4%2.6%2.5%2.8%2.8%
Free cash flow yield56.1%27.0%64.1%29.1%-11.1%-7.5%
Revenue growth6.4%0.1%18.0%20.9%16.1%22.2%
Earnings growth5.0%-0.3%7.7%0.6%11.5%10.0%
Current ratio3.64x1.16x1.02x2.39x1.96x0.94x
Debt to equity2.49x2.78x2.79x3.02x2.97x3.04x
Equity ratio22.9%21.9%21.6%20.3%21.1%20.2%
Interest coverage43.93x60.87x82.75x292.38x286.26x236.68x
R&D as a share of sales0.5%0.5%0.3%0.4%0.3%0.2%
Buybacks as a share of market value-0.7%3.5%-0.1%-0.5%-20.6%0.0%

Growth per year

Compound annual rate

3 years5 years10 years
Revenue7.9%12.0%20.8%
Operating income-33.4%-15.9%13.6%
Net income4.1%4.8%12.9%

Average margins

Over each period

1 year3 years5 years10 years
Gross margin34.2%48.6%61.4%60.4%
Operating margin21.7%36.9%49.5%47.7%
Net margin15.3%15.7%17.0%19.5%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Price to earnings4.23.83.53.94.24.14.95.68.19.7
Price to sales0.60.60.50.70.80.91.21.82.73.1

Dividends and splits

Per share, in the currency the company pays

Paid for 10 years. Last went ex-dividend on 26 Jun 2026.

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Paid in the year0.360.350.390.340.360.310.290.27

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.